Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9110400 | 0.85 | ALDH1A1 (0.48) | MAPTALDH1A1LMNAMTNR1AMTNR1B | |
| SCHEMBL15295447 | 0.82 | ALDH1A1 (0.51) | MAPTALDH1A1LMNAMAPK1NPC1 | |
| SCHEMBL9112581 | 0.79 | ALDH1A1 (0.56) | MAPTALDH1A1MTNR1AMTNR1BMAPK1 | |
| SCHEMBL9114780 | 0.77 | MTNR1A (0.47) | MTNR1AMTNR1B | |
| SCHEMBL13306853 | 0.77 | MAPT (0.50) | MAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL20982738 | 0.76 | MAPT (0.66) | MAPTALDH1A1LMNAMAPK1NPC1 | |
| SCHEMBL9114739 | 0.76 | MTNR1A (0.58) | MTNR1AMTNR1BTDP1 | |
| SCHEMBL11052562 | 0.76 | MAPT (0.61) | MAPTALDH1A1LMNAMAPK1TSHR | |
| SCHEMBL11816404 | 0.74 | MAPT (0.59) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL12281044 | 0.74 | ALDH1A1 (0.47) | MAPTALDH1A1LMNAMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | MAPT 3593/4885ALDH1A1 450/4885LMNA 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.